PT811062E - Geração de células t citotóxicas humanas específicas para antigenes auto-associados a carcinomas e suas utilizações - Google Patents

Geração de células t citotóxicas humanas específicas para antigenes auto-associados a carcinomas e suas utilizações Download PDF

Info

Publication number
PT811062E
PT811062E PT96907061T PT96907061T PT811062E PT 811062 E PT811062 E PT 811062E PT 96907061 T PT96907061 T PT 96907061T PT 96907061 T PT96907061 T PT 96907061T PT 811062 E PT811062 E PT 811062E
Authority
PT
Portugal
Prior art keywords
generation
associated antigens
cells specific
human cytotoxic
carcinoma self
Prior art date
Application number
PT96907061T
Other languages
English (en)
Inventor
Kwong Y Tsang
Jeffrey Schlom
Dennis Panicali
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of PT811062E publication Critical patent/PT811062E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT96907061T 1995-02-22 1996-02-13 Geração de células t citotóxicas humanas específicas para antigenes auto-associados a carcinomas e suas utilizações PT811062E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/396,385 US6001349A (en) 1995-02-22 1995-02-22 Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Publications (1)

Publication Number Publication Date
PT811062E true PT811062E (pt) 2009-09-28

Family

ID=23566990

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96907061T PT811062E (pt) 1995-02-22 1996-02-13 Geração de células t citotóxicas humanas específicas para antigenes auto-associados a carcinomas e suas utilizações

Country Status (10)

Country Link
US (2) US6001349A (pt)
EP (1) EP0811062B1 (pt)
JP (1) JP4059920B2 (pt)
AU (1) AU711899B2 (pt)
CA (1) CA2213451C (pt)
DE (1) DE69637969D1 (pt)
DK (1) DK0811062T3 (pt)
ES (1) ES2329427T3 (pt)
PT (1) PT811062E (pt)
WO (1) WO1996026271A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
EP2112225A1 (en) * 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO1999008713A1 (en) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
ES2286530T3 (es) * 1997-10-10 2007-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos antagonistas del antigeno carcinoembrionario (cea).
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
EP1447414B1 (en) * 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonist peptides of carcinoembryonic antigen (CEA)
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1305414A2 (en) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modified cea and uses thereof
EP1313505A4 (en) * 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
WO2003082317A1 (en) * 2002-03-22 2003-10-09 Zycos, Inc. Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
RU2334235C2 (ru) * 2002-06-11 2008-09-20 Мерк Патент Гмбх Способ картирования и устранения эпитопов т-клеток
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2005058937A2 (en) * 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP2023954B1 (en) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
US9804163B2 (en) 2010-08-06 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
JP2018526034A (ja) 2015-09-10 2018-09-13 アフィジェン・インコーポレイテッド 腫瘍治療薬の配列決定により導かれる選択
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
ES2059330T3 (es) * 1986-08-13 1994-11-16 Miles Inc Un cdna codificador de antigeno carcinoembrionico.
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5764734A (en) * 1994-12-21 1998-06-09 Motorola, Inc. Method and system for controlling access to a channel

Also Published As

Publication number Publication date
AU5024096A (en) 1996-09-11
JP4059920B2 (ja) 2008-03-12
CA2213451C (en) 2013-11-12
WO1996026271A1 (en) 1996-08-29
ES2329427T3 (es) 2009-11-25
AU711899B2 (en) 1999-10-21
EP0811062B1 (en) 2009-07-15
EP0811062A1 (en) 1997-12-10
US6319496B1 (en) 2001-11-20
DE69637969D1 (de) 2009-08-27
CA2213451A1 (en) 1996-08-29
JPH11507804A (ja) 1999-07-13
US6001349A (en) 1999-12-14
DK0811062T3 (da) 2009-10-26

Similar Documents

Publication Publication Date Title
PT811062E (pt) Geração de células t citotóxicas humanas específicas para antigenes auto-associados a carcinomas e suas utilizações
EP0956000A4 (en) SYNTHESIS OF GLYCOPHOSPHOLIPID AND PEPTIDE-PHOSPHOLIPID CONJUGATES AND THEIR USE
PL329930A1 (en) Antigens of human lymphocytes b and related reagents
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
HK1096974A1 (en) Antibody against human parathormone related peptides
AU1417897A (en) Hygienic panty and quick-attach pad
AU9577798A (en) Adjustable high chair and carrier
IL120902A0 (en) Interferon conjugates their preparation and pharmaceutical compositions containing them
EP0854878A4 (en) SYNTHES OF LEWIS-Y EPITOP GLYCOCONJUGATES AND THEIR USE
IL122215A0 (en) Dolastatin derivatives their preparation and use
EP0702793A4 (en) ANTI-CD3-ANTIBODY-AMINODEXTRON-CONJUGATES FOR INDUCTION OF -CELL ACTIVATION
NZ279605A (en) T-cell antigen receptor v region production and use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
EP0822834A4 (en) RECOMBINATION CELL (BETA) AND USES THEREOF
EP0831793A4 (en) PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
ZA952983B (en) Boronic peptide derivatives preparation and therapeutic application thereof
AU9053991A (en) Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
EP0828512A4 (en) PROTEIN (BIN1) MURINE AND HUMAN DEPENDENT ON BOXES, INTERACTING WITH MYC, AND USES THEREOF
EP0804550A4 (en) THE EX VIVO ACTIVATION OF IMMUNE CELLS
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
ZA964981B (en) Isolation of naturally occurring isoflavonone and some clinical uses thereof
EP0783510A4 (en) HUMAN PROTEINS 1 AND 2 OF POTASSICAL CHANNELS
ZA964567B (en) Oral administration of pneumococcal antigens